Novavax NVAX announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for individuals aged 12 years and older. Following this nod, Novavax’s updated vaccine is the only non-mRNA vaccine option available to people in the United States.

The FDA granted Emergency Use Authorization to Novavax's updated COVID-19 vaccine for individuals aged 12 and older. The vaccine, included in CDC recommendations, will soon be available nationwide. Novavax's shot targets the JN.

The newly approved vaccine targets multiple circulating variants, promising enhanced protection and availability across thousands of U.S. locations starting next week

The newest, updated Covid-19 vaccines are now FDA-approved and available, including the mRNA ones from Pfizer-BioNTech and Moderna and the recombinant one from Novavax.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy retailers across the U.

As COVID-19 cases continue to rise, the distribution of a newly released FDA approved vaccine is brining hope to residents of Springfield. 22News has a closer look at this updated vaccine, and how the city is trying to slow the spread.